Taiho Oncology

Taiho Oncology’s Zipalertinib Improves PFS in EGFR Lung Cancer

Princeton, New Jersey, September 15, 2026 Taiho Oncology has announced positive results from the REZILIENT3 Phase 3 trial, showing...

By cGxPwire Editor
September 15, 2026

Pharma

Taiho Oncology Advances Zipalertinib in Phase 3 Trial

Princeton, New Jersey, Tokyo, Japan & Cambridge, Massachusetts, August 12, 2026 Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced...

By cGxPwire Editor
August 14, 2026

.gov

Taiho Oncology Wins FDA Approval for INQOVI Combo

PRINCETON, N.J. and TOKYO, May 13, 2026 Taiho Oncology and Taiho Pharmaceutical announced that the U.S. Food and Drug...

By cGxPwire Editor
May 15, 2026

Bio-Pharma

Zipalertinib Advances With FDA Rolling NDA Submission

PRINCETON, NJ — November 20 , 2025 — Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced the initiation of...

By cGxPwire Editor
November 21, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

Taiho Oncology’s Zipalertinib Improves PFS in EGFR Lung Cancer

Taiho Oncology Advances Zipalertinib in Phase 3 Trial

Taiho Oncology Wins FDA Approval for INQOVI Combo

Zipalertinib Advances With FDA Rolling NDA Submission